Statement on Luis Pajuelo-Revilla | UFC

Combat Sports Anti-Doping (CSAD) announced today that Luis Pajuelo-Revilla of Tingo Maria, Huanuco, Peru, has accepted a 24-month sanction for a violation of the UFC Anti-Doping Policy (UFC ADP).

Pajuelo-Revilla tested positive for the presence of 19-norandrosterone in a urine sample and an isotope ratio mass spectrometry (IRMS) analysis that reflected values ​​consistent with the exogenous origin of testosterone and its metabolites, both banned anabolic steroids at any time collected out of competition in Lima, Peru on August 5, 2024. A later sample collected on August 21, 2024 in Pajuelo-Revilla in Sao Paulo, Brazil also tested positive for 19-norandrosterone and IRMS analysis confirmed the exogenous origin of testosterone. Pajuelo-Revilla admitted to using Deca-Durabolin (nandrolone) prior to these sample collections.

CSAD determined that an appropriate sanction for Pajuelo-Revilla's adverse findings is a 24-month suspension. Pajuelo-Revilla's suspension began on August 23, 2024, the day he was notified in writing by CSAD of his first adverse finding and received an interim suspension. Pajuelo-Revilla's ban expires 24 months later, on August 23, 2026. Following the announcement of these results and Pajuelo-Revilla's admission to using Deca-Durabolin (nandrolone), the UFC terminated his contract.

CSAD independently manages the year-round anti-doping program for all UFC athletes. All biological sampling and shipping under the UFC ADP is conducted by DFSI, the global leader in the anti-doping industry with more than 5,000 collection staff worldwide. Full UFC ADP information, including all written guidelines and athlete testing statistics, can be found at ufcantidoping.com. These policies are available in multiple languages ​​including Russian, Spanish, Portuguese, French, Korean, Japanese and Chinese.

CSAD also provides a reporting mechanism for known and suspected performance-enhancing drug abuse in the UFC at [email protected].